https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-marginal-zone-b-cell-lymphoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-212198&utm_campaign=recommended-articles-pi
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma.
b cell lymphomaregeneron pharmaceuticalsmarginal zoneodronextamab